RNA甲基化在肺癌中的研究进展

doi:10.11904/j.issn.1002-3070.2024.06.011

摘要/Abstract

摘要： 肺癌是常见的癌症之一,虽然对肺癌的风险、发展、免疫控制和治疗选择的理解有了较大的提高,但由于人们对肺癌致病机制认知有限,致其靶向治疗策略尚显不足。近年来,RNA甲基化是表观遗传学领域的研究热点,调控RNA甲基化的相关蛋白已成为癌症治疗的重要靶点。目前已有研究报道了RNA甲基化与肺癌中癌基因表达、糖酵解和免疫应答等生物过程之间的关系,但尚无深入的研究和分析。本文将从RNA甲基化与肺癌的关系入手,在现有研究的基础上探讨RNA甲基化与肺癌发病机制之间的关联,并讨论其未来发展方向。

关键词: 肺癌, m6A甲基化, 7-甲基鸟嘌呤, 5-甲基胞嘧啶, 1-甲基腺嘌呤

Abstract: Lung cancer is one of the most common cancers.Although there has been a significant improvement in our understanding the risk,development,immune control,and treatment options of lung cancer,the limited understanding of its pathogenesis has resulted in insufficient targeted treatment strategies.In recent years,RNA methylation has become a research hot topic in the field of epigenetics,and proteins regulating RNA methylation have become important targets for cancer treatment.At present,some studies have reported the relationship between RNA methylation and biological processes such as oncogene expression,glycolysis,and immune response in lung cancer,but there is still no in-depth research and analysis.This article will start with the relationship between RNA methylation and lung cancer,explore the association between RNA methylation and the pathogenesis of lung cancer based on existing research,and discuss its future development direction.

Key words: Lung cancer, M6A methylation, N7-methylguanosine, 5-methylcytosine, N1-methyladenosine

中图分类号:

R734.2

陈星燕, 李雪, 付强. RNA甲基化在肺癌中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(6): 421-426.

CHEN Xingyan, LI Xue, FU Qiang. Research progress of RNA methylation in lung cancer[J]. Journal of Practical Oncology, 2024, 38(6): 421-426.

参考文献

1 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
2 Wang LF,Wu LP,Wen JD.LncRNA AC079630.4 expression associated with the progression and prognosis in lung cancer[J].Aging(Albany NY),2021,13(14):18658-18668.
3 Teng PC,Liang Y,Yarmishyn AA,et al.RNA modifications and epigenetics in modulation of lung cancer and pulmonary diseases[J].Int J Mol Sci,2021,22:10592.
4 Schaefer M,Kapoor U,Jantsch MF.Understanding RNA modifications:the promises and technological bottlenecks of the ′epitranscriptome′[J].Open Biol,2017,7(5):170077.
5 Gu C,Shi X,Dai C,et al.RNA m6A Modification in cancers:Molecular mechanisms and potential clinical applications[J].Innovation(Camb),2020,1(3):100066.
6 Deng LJ,Deng WQ,Fan SR,et al.m6A modification:recent advances,anticancer targeted drug discovery and beyond[J].Mol Cancer,2022,21(1):52.
7 Li Y,Su R,Deng X,et al.FTO in cancer:functions,molecular mechanisms,and therapeutic implications[J].Trends Cancer,2022,8(7):598-614.
8 Qu J,Yan H,Hou Y,et al.RNA demethylase ALKBH5 in cancer:from mechanisms to therapeutic potential[J].J Hematol Oncol,2022,15(1):8.
9 Shi H,Wei J,He C.Where,when,and how:context-dependent functions of RNA methylation writers,readers,and erasers[J].Mol Cell,2019,74(4):640-650.
10 Sheng Y,Wei J,Yu F,et al.A critical role of nuclear m6A reader YTHDC1 in leukemogenesis by regulating MCM complex-mediated DNA replication[J].Blood,2021,138(26):2838-2852.
11 Li B,Zhu L,Lu C,et al.circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity[J].Nat Commun,2021,12(1):295.
12 Yin H,Chen L,Piao S,et al.M6A RNA methylation-mediated RMRP stability renders proliferation and progression of non-small cell lung cancer through regulating TGFBR1/SMAD2/SMAD3 pathway[J].Cell Death Differ,2023,30(3):605-617.
13 Hu Z,Zhu L,Zhang Y,et al.N6-methyladenosine-induced SVIL antisense RNA 1 restrains lung adenocarcinoma cell proliferation by destabilizing E2F1[J].Bioengineered,2022,13:3093-3107.
14 Ning J,Wang F,Bu J,et al.Down-regulated m6A reader FTO destabilizes PHF1 that triggers enhanced stemness capacity and tumor progression in lung adenocarcinoma[J].Cell Death Discov,2022,8(1):354.
15 Liu XS,Zhou LM,Yuan LL,et al.NPM1 Is a Prognostic biomarker involved in immune infiltration of lung adenocarcinoma and associated with m6a modification and glycolysis[J].Front Immunol,2021,12:724741.
16 Ma L,Xue X,Zhang X,et al.The essential roles of m(6)A RNA modification to stimulate ENO1-dependent glycolysis and tumorigenesis in lung adenocarcinoma[J].J Exp Clin Cancer Res,2022,41(1):36.
17 Xue L,Li J,Lin Y,et al.m6 A transferase METTL3-induced lncRNA ABHD11-AS1 promotes the Warburg effect of non-small-cell lung cancer[J].J Cell Physiol,2021,236(4):2649-2658.
18 Xu P,Hu K,Zhang P,et al.Hypoxia-mediated YTHDF2 overexpression promotes lung squamous cell carcinoma progression by activation of the mTOR/AKT axis[J].Cancer Cell Int,2022,22(1):13.
19 Wang N,Xu Y,Jin L,et al.Effects of N6-Methyladenosine Regulators on LAG3 and immune infiltrates in lung adenocarcinoma[J].Dis Markers,2022,2022:1829528.
20 Hu K,Yao L,Yan Y,et al.Comprehensive analysis of YTH domain family in lung adenocarcinoma:expression profile,association with prognostic value,and immune infiltration[J].Dis Markers,2021,2021:2789481.
21 Wu L,Cheng D,Yang X,et al.M2-TAMs promote immunoresistance in lung adenocarcinoma by enhancing METTL3-mediated m6A methylation[J].Ann Transl Med,2022,10(24):1380.
22 Shi CY,Yu CH,Yu WY,et al.Gut-Lung microbiota in chronic pulmonary diseases:evolution,pathogenesis,and therapeutics[J].Can J Infect Dis Med Microbiol,2021,2021:9278441.
23 Li Y,Gu J,Xu F,et al.Molecular characterization,biological function,tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma[J].Brief Bioinform,2021,22(4):225.
24 Guo W,Huai Q,Zhang G,et al.Elevated heterogeneous nuclear ribonucleoprotein C expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma[J].Front Oncol,2020,10:598437.
25 Guo W,Huai Q,Wan H,et al.Prognostic impact of IGF2BP3 expression in patients with surgically resected lung adenocarcinoma[J].DNA Cell Biol,2021,40(2):316-331.
26 Xiao H,Zhao R,Meng W,et al.Effects and translatomics characteristics of a small-molecule inhibitor of METTL3 against non-small cell lung cancer[J].J Pharm Anal,2023,13(6):625-639.
27 Chen B,Ye F,Yu L,et al.Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor[J].J Am Chem Soc,2012,134(43):17963-17971.
28 Huang Y,Yan J,Li Q,et al.Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5[J].Nucleic Acids Res,2015,43(1):373-384.
29 Chen WW,Qi JW,Hang Y,et al.Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA[J].Eur Rev Med Pharmacol Sci,2020,24(8):4263-4270.
30 Choe J,Lin S,Zhang W,et al.mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis[J].Nature,2018,561(7724):556-560.
31 Lin S,Liu Q,Lelyveld VS,et al.Mettl1/Wdr4-Mediated m7G tRNA Methylome is required for normal mrna translation and embryonic stem cell self-renewal and differentiation[J].Mol Cell,2018,71(2):244-255.
32 Balzeau J,Menezes MR,Cao S,et al.The LIN28/let-7 Pathway in Cancer[J].Front Genet,2017,8:31.
33 Ma J,Han H,Huang Y,et al.METTL1/WDR4-mediated m7G tRNA modifications and m7G codon usage promote mRNA translation and lung cancer progression[J].Mol Ther,2021,29(12):3422-3435.
34 Wang G,Zhao M,Li J,et al.m7G-Associated subtypes,tumor microenvironment,and validation of prognostic signature in lung adenocarcinoma[J].Front Genet,2022,13:954840.
35 Zhang C,Zhou D,Wang Z,et al.Risk model and immune signature of m7G-Related lncRNA based on lung adenocarcinoma[J].Front Genet,2022,13:907754.
36 Huang W,Qi CB,Lv SW,et al.Determination of DNA and RNA methylation in circulating tumor cells by mass spectrometry[J].Anal Chem,2016,88(2):1378-1384.
37 Li M,Tao Z,Zhao Y,et al.5-methylcytosine RNA methyltransferases and their potential roles in cancer[J].J Transl Med,2022,20(1):214.
38 Wang Y,Wei J,Feng L,et al.Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2/YBX1/QSOX1 axis in EGFR-mutant non-small-cell lung cancer[J].Mol Cancer,2023,22(1):81.
39 Chen Z,Qi M,Shen B,et al.Transfer RNA demethylase ALKBH3 promotes cancer progression via induction of tRNA-derived small RNAs[J].Nucleic Acids Res,2019,47(5):2533-2545.
40 Tasaki M,Shimada K,Kimura H,et al.ALKBH3,a human AlkB homologue,contributes to cell survival in human non-small-cell lung cancer[J].Br J Cancer,2011,104(4):700-706.

[1]	徐仙会, 陈杨, 朱云芳, 李明松, 文洪梅. 2020年云南省肿瘤登记地区肺癌发病和死亡情况及2012—2020年趋势分析[J]. 实用肿瘤学杂志, 2024, 38(6): 367-371.
[2]	郝慧婷, 赵惠娟, 徐巧慧. 癌症高甲基化1在非小细胞肺癌中的表达及其临床意义[J]. 实用肿瘤学杂志, 2024, 38(5): 306-312.
[3]	徐灵燕, 李倩妮, 李健, 姚雪佩, 刘美娜. 非小细胞肺癌患者首次住院天数对治疗质量的影响分析[J]. 实用肿瘤学杂志, 2024, 38(4): 221-226.
[4]	姚雪佩, 白山奇, 刘美娜. 基于因果图模型的非小细胞肺癌治疗质量影响因素分析[J]. 实用肿瘤学杂志, 2024, 38(4): 227-234.
[5]	李健, 李倩妮, 徐灵燕, 姚雪佩, 刘美娜. 基于双重稳健估计方法的非小细胞肺癌治疗过程对院内死亡的因果效应研究[J]. 实用肿瘤学杂志, 2024, 38(4): 235-240.
[6]	马娜, 刘捷. 天津市河东区2015—2020年肺癌发病与死亡情况分析[J]. 实用肿瘤学杂志, 2024, 38(4): 241-245.
[7]	程泳铭, 董欢欢, 徐晖. Hsa-let-7b-5p抑制非小细胞肺癌的增殖、迁移和侵袭[J]. 实用肿瘤学杂志, 2024, 38(3): 157-167.
[8]	王文博, 白海昕, 张弹, 牛丽. 异丙酚通过GLUT4抑制肺癌糖酵解及肿瘤进展[J]. 实用肿瘤学杂志, 2024, 38(2): 104-111.
[9]	薄芸, 杭文璐, 左淑润, 董圆, 李海泉. 长链非编码RNA OTUD6B-AS1对肺腺癌A549细胞增殖、侵袭和迁移能力的影响[J]. 实用肿瘤学杂志, 2024, 38(1): 13-17.
[10]	张萱, 李欣, 赵康. 血清炎性标志物与一线免疫抑制剂治疗晚期非小细胞肺癌患者预后的关系[J]. 实用肿瘤学杂志, 2024, 38(1): 37-44.
[11]	苗玲, 赵之寒, 王敏. 非小细胞肺癌患者肿瘤组织PA28γ、miR-7-5p的表达水平及临床意义[J]. 实用肿瘤学杂志, 2023, 37(4): 344-350.
[12]	曹莹月, 庞露薏, 张键, 金时. 癌相关成纤维细胞在非小细胞肺癌进展中的作用[J]. 实用肿瘤学杂志, 2023, 37(4): 383-388.
[13]	韦虹, 王曌曦, 王一淳, 周显礼. 超声造影联合声辐射力脉冲成像在周围型肺占位中的临床应用价值研究[J]. 实用肿瘤学杂志, 2023, 37(3): 236-242.
[14]	陈琪, 何明旭, 贾科良, 苗健龙, 韩丽萍. TP53-EGFR共突变对非小细胞肺癌预后及治疗的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 262-266.
[15]	龙朝恋, 李琨, 刘子臣, 张娜娜, 车南颖. 非小细胞肺癌程序性死亡配体-1表达与临床病理特征和常见驱动基因变异的相关性研究[J]. 实用肿瘤学杂志, 2023, 37(2): 117-122.